Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by KayakerBCon Jun 30, 2022 4:13pm
164 Views
Post# 34794961

RE:Upcoming financing at $0.15?

RE:Upcoming financing at $0.15?Dang, it's not happening today.  It's still many months away.  That question starts at 38:00 in the Webinar -- funding will be stepped, conscious of current market conditions and stock price, don't want to unduly dilute shareholders, working with Ladenburg Thalmann.

Possible deal (or whatever) for XB3-001 coming before that, as discussed here.  Other stock boosting events in the second half of the year?, e.g., progress to the clinic from a partner?  Maybe.  Perhaps.


<< Previous
Bullboard Posts
Next >>